Disclosed is the use of a recombinant human Angiotensin converting enzyme 2 ( ACE2 ) protein for the production of a pharmaceutical composition for the treatment or prevention of a fibrosis, such as liver fibrosis resulting from hepatitis or caused by an infection or wound.